PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28403051
OWN - NLM
STAT- MEDLINE
DA  - 20170413
DCOM- 20170420
LR  - 20170420
IS  - 1532-0987 (Electronic)
IS  - 0891-3668 (Linking)
VI  - 36
IP  - 5
DP  - 2017 May
TI  - Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children
      Receiving Antiretroviral Therapy.
PG  - e123-e129
LID - 10.1097/INF.0000000000001478 [doi]
AB  - BACKGROUND: The effect of hepatitis C virus (HCV) coinfection on CD4 T cell
      recovery in treated HIV-infected children is poorly understood. OBJECTIVE: To
      compare CD4 T cell recovery in HIV/HCV coinfected children with recovery in HIV
      monoinfected children. METHOD: We studied 355 HIV monoinfected and 46 HIV/HCV
      coinfected children receiving antiretroviral therapy (ART) during a median
      follow-up period of 4.2 years (interquartile range: 2.7-5.3 years). Our dataset
      came from the Ukraine pediatric HIV Cohort and the HIV/HCV coinfection study
      within the European Pregnancy and Paediatric HIV Cohort Collaboration. We fitted 
      an asymptotic nonlinear mixed-effects model of CD4 T cell reconstitution to
      age-standardized CD4 counts in all 401 children and investigated factors
      predicting the speed and extent of recovery. RESULTS: We found no significant
      impact of HCV coinfection on either pre-ART or long-term age-adjusted CD4 counts 
      (z scores). However, the rate of increase in CD4 z score was slower in HIV/HCV
      coinfected children when compared with their monoinfected counterparts (P <
      0.001). Both monoinfected and coinfected children starting ART at younger ages
      had higher pre-ART (P < 0.001) and long-term (P < 0.001) CD4 z scores than those 
      who started when they were older. CONCLUSIONS: HIV/HCV coinfected children
      receiving ART had slower CD4 T cell recovery than HIV monoinfected children.
      HIV/HCV coinfection had no impact on pre-ART or long-term CD4 z scores. Early
      treatment of HIV/HCV coinfected children with ART should be encouraged.
FAU - Majekodunmi, Adedeji O
AU  - Majekodunmi AO
AD  - From the *Institute of Child Health, and daggerCoMPLEX: Centre for Mathematics
      and Physics in the Life Sciences and Experimental Biology, University College
      London, London, United Kingdom; double daggerPerinatal Prevention of AIDS
      Initiative, Odessa, Ukraine; section signShupyk National Medical Academy of
      Postgraduate Education, Kiev, Ukraine; paragraph signGreat Ormond Street
      Hospital, and ||Department of Infectious Disease Epidemiology, Imperial College
      London, St Mary's Campus, London, United Kingdom.
FAU - Thorne, Claire
AU  - Thorne C
FAU - Malyuta, Ruslan
AU  - Malyuta R
FAU - Volokha, Alla
AU  - Volokha A
FAU - Callard, Robin E
AU  - Callard RE
FAU - Klein, Nigel J
AU  - Klein NJ
FAU - Lewis, Joanna
AU  - Lewis J
CN  - European Paediatric HIV/HCV Co-infection Study group in the European Pregnancy
      and Paediatric HIV Cohort Collaboration and the Ukraine Paediatric HIV Cohort
      Study in EuroCoord
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Infect Dis J
JT  - The Pediatric infectious disease journal
JID - 8701858
RN  - 0 (Antiviral Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 0 (lopinavir-ritonavir drug combination)
RN  - 2494G1JF75 (Lopinavir)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 30IQX730WE (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - 4B9XT59T7S (Zidovudine)
RN  - O3J8G9O825 (Ritonavir)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - *Antiretroviral Therapy, Highly Active
MH  - Antiviral Agents/*therapeutic use
MH  - CD4 Lymphocyte Count
MH  - CD4-Positive T-Lymphocytes/*immunology/virology
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Coinfection
MH  - Drug Combinations
MH  - Female
MH  - HIV Infections/*drug therapy/immunology/virology
MH  - HIV-1/drug effects/immunology
MH  - Hepacivirus/drug effects/immunology
MH  - Hepatitis C/*drug therapy/immunology/virology
MH  - Humans
MH  - Interferon-alpha/therapeutic use
MH  - Lamivudine/therapeutic use
MH  - Lopinavir/therapeutic use
MH  - Male
MH  - *Models, Immunological
MH  - Polyethylene Glycols/therapeutic use
MH  - Recombinant Proteins/therapeutic use
MH  - Recovery of Function/immunology
MH  - Ribavirin/therapeutic use
MH  - Ritonavir/therapeutic use
MH  - Time-to-Treatment
MH  - Zidovudine/therapeutic use
PMC - PMC5380220
MID - EMS70692
EDAT- 2017/04/14 06:00
MHDA- 2017/04/21 06:00
CRDT- 2017/04/14 06:00
PMCR- 2018/06/15
AID - 10.1097/INF.0000000000001478 [doi]
AID - 00006454-201705000-00011 [pii]
PST - ppublish
SO  - Pediatr Infect Dis J. 2017 May;36(5):e123-e129. doi:
      10.1097/INF.0000000000001478.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>